Background: The bioavailability of g-tocopherol and metabolites of vitamin E after g-tocopherol administration is not well understood. We investigated the effect of g-tocopherol administration on the levels and metabolism of a-and g-tocopherol in healthy volunteers. Methods: We measured two metabolites of vitamin E (2,5,7,8-tetramethyl-2-(2 0 -carboxyethyl)-6-hydroxychroman (a-CEHC) and 2,7,8-trimethyl-2-(2 0 -carboxyethyl)-6-hydroxychroman (g-CEHC)) in plasma and urine by high-performance liquid chromatography with electrochemical detection (HPLC-ECD) during administration of g-tocopherol. Two groups of volunteers were enrolled. The g-tocopherol group received two g-tocopherol capsules (each containing 186.4 mg of g-tocopherol and 5 mg of a-tocopherol) for 28 days, while the control group received d-a-tocopherol at 5 mg/day, which was the same dose as that given to the g-tocopherol group. Blood and urine samples were obtained on days 0, 14, 28, 35, 42, and 56 after the initiation of g-tocopherol administration. Results: The plasma g-tocopherol concentration increased markedly during administration of g-tocopherol and the plasma g-CEHC concentration increased along with that of g-tocopherol. The plasma a-tocopherol concentration decreased significantly during g-tocopherol administration. The plasma concentration of a-CEHC decreased significantly and urinary excretion of a-CEHC tended to increase in the g-tocopherol group. Urinary sodium secretion was significantly increased at 1 week after the cessation of g-tocopherol administration, but there was no significant difference of urine volume between the two groups. Conclusion: Metabolism of a-tocopherol is accelerated and the plasma a-tocopherol concentration is decreased during g-tocopherol administration.
Introduction
Recent studies have indicated that g-tocopherol might be important for human health and that it possesses unique features (Jiang et al, 2001) . After g-tocopherol is absorbed, it accumulates significantly in some human tissues. It is largely metabolized to 2,7,8-trimethyl-2-(2 0 -carboxyethyl)-6-hydroxychroman (g-CEHC), which shows some interesting physiological properties. The natriuretic activity of g-CEHC is mediated via inhibition of 70 pS ATP-sensitive K þ channels in the thick ascending limb of the loop of Henle (Wechter et al, 1996; Murray Jr et al, 1997) . Both g-tocopherol and g-CEHC inhibit cyclooxygenase and show an anti-inflammatory effect (Jiang et al, 2000; Jiang & Ames, 2003; Grammas et al, 2004) . Some studies have indicated that the plasma concentration of g-tocopherol is inversely associated with the incidence of cardiovascular disease and prostate cancer (Jiang et al, 2001; Huang et al, 2003; Hensley et al, 2004) . Studies by Liu have suggested that mixed tocopherols are more effective at preventing platelet aggregation and increasing nitric-oxide (NO) release, as well as activating endothelial constitutive nitric-oxide synthase (ecNOS) and increasing the superoxide dismutase (SOD) protein content in platelets (Liu et al, 2003) . Moreover, g-tocopherol might be protective against nitrative stress (Williamson et al, 2002) . There have been various reports on tocopherol metabolism in patients with renal disease (Himmelfarb et al, 2003; Smith et al, 2003; Galli et al, 2004) . In particular, Himmelfarb et al (2003) suggested that accumulation of a-CEHC and g-CEHC occurs in uremic patients compared with healthy subjects and that accumulation of CEHC may have anti-inflammatory and antioxidant effects in hemodialysis patients. Although use of g-tocopherol as a supplement has attracted attention, its metabolism in humans is not clearly understood. Radosavac et al (2002) investigated the plasma levels of tocopherols and CEHCs after ingestion of a single dose of vitamin E (306 mg of RRR-a-tocopherol and 1.77 mg of g-tocopherol) and found a significant increase in serum a-tocopherol and a-CEHC levels. Although the g-tocopherol level decreased in their study, an increase in its metabolite g-CEHC was observed (Radosavac et al, 2002) . We previously investigated the serum and urine levels of a-and g-CEHC in humans, and reported the elevation of both a-and g-CEHC after high-dose a-tocopherol administration. The decrease in g-tocopherol after a-tocopherol supplementation is considered to be due to the acceleration of g-tocopherol metabolism (Morinobu et al, 2003) . Kiyose detected the excretion of g-CEHC in vitamin E-deficient rats receiving a-and g-tocopherol supplementation, and suggested that a-tocopherol might influence the transformation of g-tocopherol to g-CEHC (Kiyose et al, 2001) . Regarding the vitamin E metabolism after g-tocopherol administration, Clement studied rats fed a diet with a constant content of RRR-atocopherol plus various amounts of RRR-g-tocopherol, and found that the tissue levels of a-tocopherol were much higher than those in rats fed a control diet containing RRR-atocopherol alone (Clement & Bourre, 1997) . Galli administered a single dose of deuterium-labeled g-tocopherol acetate to humans and investigated a-, g-tocopherol and a-, g-CEHC concentration (Galli et al, 2003) . But there has been no report on the metabolism of vitamin E after chronically administering g-tocopherol.
In the present study, we administered g-tocopherol to healthy adult male volunteers for 28 days, and investigated its influence on the metabolism of a-and g-tocopherol as well as the natriuretic effect of g-tocopherol supplementation.
Subjects and methods

Chemicals
Both a-and g-tocopherol as well as a-and g-CEHC were obtained from Eisai Co. (Tokyo, Japan). In addition, bglucuronidase derived from E.coli, butylated hydroxytoluene (BHT) hydrochloride, hexane, diethylether, dichloromethane, and ascorbic acid were obtained from Nacalai Tesque Co. (Kyoto, Japan).
Subjects
A total of 13 healthy adult male volunteers were enrolled in this study. Their mean age was 28.6 (s.d. 3.2) y. None of them were taking regular vitamin supplements. We randomly divided the 13 subjects into a group that was given gtocopherol capsules (n ¼ 7; the g-Toc group) and a control group (n ¼ 6). The g-Toc group received two g-tocopherol capsules/day. One capsule was given after breakfast and the other one after supper. (The amount of tocopherol content in each capsule was d-a: 2.5 mg, d-b:
2.3 mg, respectively.) The control group received 5 mg of d-atocopherol daily: into 2.5 mg in the morning and 2.5 mg in the evening. The 2.5 mg of cf-a-tocopherol powder was mixed in 0.2 g of lactose. In both groups, administration was done for 28 days. After an overnight fast, blood was obtained from each volunteer on days 0 (before administration), 14, 28, 35, 42, and 56 of administration. A 24-h urine sample was also obtained from each volunteer on the days of blood testing. We performed a dietary study on all the volunteers over 7 days, and calculated dietary intake of tocopherols and sodium (Table 1 ). This study was approved by the ethics committee of Osaka Medical College, and written informed consent was obtained from each subject.
Analysis of vitamin E
A volume of 200 ml of plasma was placed into a tube together with 800 ml of phosphate buffer, 1 ml of 6% pyrogallol solution in ethanol, and 1 ml of tocol solution in ethanol (2 mg/ml) as an internal standard. Then preincubation was performed for 2 min at 701C. After this, 0.2 ml of 60% KOH was added and the mixture was saponified at 701C for 30 min. Following saponification, the solution was mixed with 5 ml of n-hexane and vigorously shaken for 5 min. After centrifugation at 3000 r.p.m. for 5 min, 4 ml of the hexane layer was collected and evaporated to dryness. The residue was dissolved in 100 ml of ethanol, and a 5-ml aliquot was injected into the HPLC-ECD system (Tamai et al, 1988) .
Analysis of CEHC
The concentrations of CEHC in urine and plasma were measured by HPLC-ECD (Morinobu et al, 2003) . b-Glucuronidase (25 000 units) was dissolved in 2.5 ml of 0.1 mol/l acetate buffer (pH 4.5) on ice and used to hydrolyze the conjugate immediately after preparation. Urine (1 ml) was placed into a tube together with 1000 U (0.1 ml) of bglucuronidase and incubated for 4 h at 371C to achieve hydrolysis. After cooling on ice, 50 ml of 6 mol/l HCl and 3 ml of diethylether were added, the mixture was centrifugated at 2000 r.p.m. for 2 min, and 2 ml of the diethylether layer was collected and evaporated to dryness. The residue was Mean7s.e.m. (tocopherol, mg/day; NaCl, g/day).
Tocopherol metabolism during administration of c-tocopherol S Yoshikawa et al dissolved in 4 ml of ethanol with 0.015% BHT, after which 20-ml aliquots of the resulting solution were injected into the HPLC system. In all, 500 ml of serum was prepared, and 25 ml of ascorbic acid (10 mg/ml water) and 2000 U of b-glucuronidase were added. After incubation for 1 h at 371C and cooling, 5 ml of extraction solvent (50% hexane, 50% dichloromethane, and 0.1% BHT) was pipetted into the mixture. After vortexing and centrifugation at 5000 r.p.m. for 5 min, 4 ml of the supernatant was taken and evaporated to dryness. Then the residue was dissolved in 200 ml of acetonitrile/H 2 O (2:3) solvent and a 20 ml aliquot was injected into the HPLC-ECD system.
The HPLC system consisted of an IRICA P 871 pump (IRICA Co Ltd, Kyoto, Japan), a Nano Space Amperometer (Shiseido Co Ltd, Tokyo, Japan) with an applied potential of 550 mV, and an ODSIII C18 column (5 mm, 2.1 Â 250 mm, GL Science). The column temperature was set at 371C. Elution was done with a mixture of 40% acetonitrile and 60% H 2 O containing 50 mmol/l NaClO 4 (pH 3.6), and the flow rate was set at 0.2 ml/min.
The dietary vitamin E content was calculated from the dietary tocopherol intake based on the 5th revised Standard Tables of Food Composition in Japan (Resources Council, 2000) .
Statistics
All results are expressed as the mean7s.e.m. Statistical significance was calculated by Student's t-test using Stat View 4.0 software (Abacus Concepts, Inc., CA, USA).
Results
The daily dietary intake of tocopherol is shown in Table 1 . The a-tocopherol equivalent intake (a-Toc-eq) was calculated as the a-tocopherol content plus 1/10 of the g-tocopherol content. The daily a-Toc-eq was below the recommended daily allowance (RDA) for Japan (10 mg/day) in both the gToc group and the control group. There were no significant differences of a-Toc-eq and sodium intake between both groups.
The figure shows the changes of tocopherol and CEHC levels in plasma and urine. The plasma g-tocopherol concentration increased markedly during administration of g-tocopherol (Figure 1) , while the plasma a-tocopherol level decreased significantly (Figure 2 ). After the completion of administration, these changes resolved within a week. The plasma g-CEHC concentration increased markedly along with changes of the g-tocopherol concentration in the gToc group (Figure 3) , while the plasma a-CEHC concentration decreased along with the a-tocopherol concentration. Although the plasma a-CEHC level in the g-Toc group was higher than that of the control group before administration, there was no significant difference between the two groups ( Figure 4) . The plasma concentrations of both metabolites were restored to baseline within a week of the completion of administration. Urinary g-CEHC increased in the g-Toc group ( Figure 5 ) and a-CEHC also tended to increase despite a decrease in plasma a-CEHC (Figure 6 ). In contrast, no marked changes of urinary metabolites were observed in the control group. In the g-Toc group, urinary sodium excretion was significantly increased at one week after the cessation of g-tocopherol administration (Table 2) Tocopherol metabolism during administration of c-tocopherol S Yoshikawa et al were no significant differences of urine volume between the two groups (Table 3) .
Discussion
Tocopherol metabolism, especially that of g-tocopherol or gtocotrienol, and the effects of tocopherols on sodium secretion in rats have been examined by various authors (Clement & Bourre, 1997; Hattori et al, 2000a; Kiyose et al, 2001; Ikeda et al, 2002; Saito et al, 2003) . Kiyose et al (2001) investigated the differences of g-CEHC excretion in urine and bile after the oral administration of g-tocopherol or a-þ g-tocopherol to rats, and concluded that a-tocopherol may influence the in vivo metabolism of g-tocopherol to g-CEHC.
In our previous study, a marked elevation of the plasma atocopherol level and a converse decrease in g-tocopherol were observed during high-dose a-tocopherol administration (Morinobu et al, 2003) . This suggests that accelerated metabolism of g-tocopherol during a-tocopherol administration might be due to the induction of a catabolic enzyme.
In the present study, the plasma g-tocopherol concentration showed a significant increase from 3.9 to 15.0 mmol/l in the g-Toc group and the plasma a-tocopherol concentration showed a significant decrease from 19.8 to 14.7 mmol/l, even though each capsule contained 2.5 mg of a-tocopherol. In addition, the plasma a-CEHC concentration was significantly decreased and urinary a-CEHC excretion tended to increase in the g-Toc group. In the liver, a-TTP specifically selects a-tocopherol from among all the incoming tocopherols for incorporation into VLDL and transfer to the plasma (Traber et al, 1990 ). a-TTP shows the highest affinity for RRRa-tocopherol, whereas its affinity for g-tocopherol is only 9% (Hosomi et al, 1997) , so the plasma level of g-tocopherol would be expected to be lower than that of a-tocopherol. In our study, excess g-tocopherol was taken up by the liver, so more g-tocopherol combined with a-TTP than usual. Therefore, the amount of a-tocopherol bound to a-TTP and transferred to the blood might have decreased, leading to a decrease in the plasma a-tocopherol concentration and an increase in hepatic a-tocopherol metabolism to a-CEHC.
There have also been some reports about the effects of gtocopherol or g-tocotrienol in humans (Lodge et al, 2001; Galli et al, 2002 Galli et al, , 2003 . In the study of Galli, a single bolus of 100 mg of deuterium-labeled g-tocopherol acetate (g-TAC) was administered to 21 healthy subjects. They concluded that supplementation with 100 mg of g-TAC did not influence a-tocopherol plasma concentrations or its catabolism. According to Lodge, urinary a-CEHC excretion was not affected by g-tocotrienyl acetate supplementation and urinary g-CEHC excretion was not affected by a-tocotrienyl acetate supplementation. But in the present study, plasma atocopherol and a-CEHC concentrations significantly decreased after g-tocopherol administration. Clement et al reported that massive supplementation of vitamin E-deficient rats with g-tocopherol plus a-tocopherol resulted in an increase in the plasma a-tocopherol concentration (Clement & Bourre, 1997) , while a slight (but significant) decrease in atocopherol was observed when the rats were supplemented with g-tocopherol alone. These findings are in agreement with our results. Thus, there have been different results about the effect of g-tocopherol administration on the atocopherol level. We have no adequate explanation for the contrary results, but factors that might be contributory include the use of a vitamin-deficient model, different doses of tocopherol, use of the natural form or acetate of Tocopherol metabolism during administration of c-tocopherol S Yoshikawa et al g-tocopherol, and mode of administration (a single bolus dose vs administration for 28 days). Both the plasma a-CEHC concentration and the urinary a-CEHC excretion were expected to increase, but their changes were opposite in this study. g-CEHC and a-CEHC are excreted after glucuronidation. To facilitate the excretion of g-CEHC, glucuronidation is more promoted, and this glucuronidation might not only affect g-CEHC but also a-CEHC. Hattori et al (2000a, b) reported that LLU-a (g-CEHC) was found in urine and also in bile, suggesting that enterohepatic circulation may occur. The decrease in the plasma a-CEHC concentration detected in the present study might have been due to accelerated glucronidation because of the increase in g-CEHC and/or enterohepatic circulation of a-CEHC.
g-CEHC was originally discovered as a natriuretic factor (Wechter et al, 1996) , but there have not been any reports that g-CEHC increases urinary sodium excretion in humans. Saito et al (2003) investigated whether natriuresis and diuresis were induced by one of the major vitamin E homologs, g-tocotrienol, and its metabolite g-CEHC in vivo. They concluded that g-tocotrienol promotes sodium excretion and increases urine output in rats on a high-sodium diet due to its activity as an endogenous natriuretic hormone regulating the extracellular volume. Accordingly, g-tocotrienol may only stimulate sodium excretion and increase urine output in the presence of a high sodium intake. In our study, urinary sodium excretion was increased (although not significantly) on day 28 in the g-Toc group, and was significantly increased at 1 week after the cessation of gtocopherol administration in the presence of a normal sodium intake, while urinary g-CEHC excretion was still elevated on days 28 and 35. We suspect that this increase in g-CEHC excretion might have promoted urinary sodium excretion, but the precise mechanism involved is unknown. There was no significant difference of urine output between the two groups, but it tended to be higher in the g-Toc group at 1 week after the completion of administration. However, we cannot confirm that g-tocopherol and/or g-CEHC have natriuretic activity. Further investigations will be required to test more doses of g-tocopherol with controlled water intake, so that higher blood levels of g-tocopherol and g-CEHC may have a significant influence on urinary parameters.
In conclusion, the present study showed that the plasma gtocopherol concentration was increased markedly during the administration of g-tocopherol capsules, while the plasma and urinary g-CEHC concentrations increased along with the changes of g-tocopherol. In addition, a-tocopherol metabolism was accelerated and the plasma a-tocopherol level was decreased during g-tocopherol administration. Although urinary sodium excretion may be promoted by g-tocopherol administration, there is little increase in urine output. Further investigations are required to examine the natriuretic activity of g-CEHC in more detail.
